Organon (OGN) Non-Current Debt (2021 - 2026)
Organon (OGN) posted quarterly Non-Current Debt of $8.6 billion for Q1 2026, down 4.29% year-over-year from $8.9 billion in Q1 2025, and down 0.87% on a QoQ basis from $8.6 billion in Q4 2025.
Organon (OGN) Non-Current Debt (2021 - 2026) Analysis & Trends
Organon (OGN) has reported Non-Current Debt for 6 consecutive years, with $8.6 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt fell 4.29% year-over-year to $8.6 billion; the TTM figure through Mar 2026 stood at $8.6 billion (down 4.29% YoY), while the FY2025 annual figure was $8.6 billion, down 2.62% from the prior year.
- Non-Current Debt came in at $8.6 billion for Q1 2026 at Organon, down from $8.6 billion in the prior quarter.
- The five-year high for Non-Current Debt was $9.1 billion in Q1 2022, with the low at $8.6 billion in Q1 2026.
- Average Non-Current Debt over 5 years is $8.8 billion, with a median of $8.7 billion recorded in 2024.
- Across the five-year window, Non-Current Debt declined 6.13% in 2022 and advanced 2.65% in 2025, its largest moves.
- Year by year, Non-Current Debt stood at $8.9 billion in 2022, then fell by 1.73% to $8.8 billion in 2023, then grew by 1.25% to $8.9 billion in 2024, then slipped by 2.62% to $8.6 billion in 2025, then retreated by 0.87% to $8.6 billion in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $8.6 billion, $8.6 billion, and $8.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 39.37 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 37.53 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 64.53 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -24.45 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 46.67 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 51.89 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 20.86 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 60.57 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn | 8.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.55 Bn |
| Dec 31, 2025 | 8.63 Bn |
| Sep 30, 2025 | 8.78 Bn |
| Jun 30, 2025 | 8.78 Bn |
| Mar 31, 2025 | 8.94 Bn |
| Dec 31, 2024 | 8.86 Bn |
| Sep 30, 2024 | 8.74 Bn |
| Jun 30, 2024 | 8.65 Bn |
| Mar 31, 2024 | 8.71 Bn |
| Dec 31, 2023 | 8.75 Bn |
| Sep 30, 2023 | 8.65 Bn |
| Jun 30, 2023 | 8.72 Bn |
| Mar 31, 2023 | 8.70 Bn |
| Dec 31, 2022 | 8.91 Bn |
| Sep 30, 2022 | 8.69 Bn |
| Jun 30, 2022 | 8.88 Bn |
| Mar 31, 2022 | 9.09 Bn |
| Dec 31, 2021 | 9.13 Bn |
| Sep 30, 2021 | 9.26 Bn |
| Jun 30, 2021 | 9.31 Bn |